CTOR vs MCK

McKesson Corporation (MCK) offers the better valuation at 28.

9x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Citius Oncology, Inc. (CTOR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to -92. 0% for Citius Oncology, Inc. (CTOR). Over 10 years, the gap is even starker: MCK returned +351. 9% versus CTOR's -92. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Citius Oncology, Inc. 's 1. 86β — meaning CTOR is approximately 4219% more volatile than MCK relative to the S&P 500.

On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14.

9% year-over-year, compared to -13. 3% for Citius Oncology, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus 0. 0% for Citius Oncology, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus 0. 0% for CTOR. At the gross margin level — before operating expenses — MCK leads at 3. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CTOR: 559.

8% to $6. 00.

In this comparison, MCK (0.

4% yield) pays a dividend. CTOR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). Citius Oncology, Inc. (CTOR) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +351. 9%, CTOR: -92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTOR is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.